Maze Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAZE research report →
About the company
Maze Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
- CEO
- Jason Coloma
- IPO
- 2025
- Employees
- 141
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $1.73B
- P/E
- -11.37
- P/S
- 86.50
- P/B
- 4.93
- EV/EBITDA
- -13.33
- Div Yield
- 0.00%
- Gross Margin
- 92.04%
- Op Margin
- -670.25%
- Net Margin
- -612.71%
- ROE
- -36.63%
- ROIC
- -33.24%
- Revenue
- $0 · -100.00%
- Net Income
- $-131,120,000 · -351.04%
- EPS
- $-3.05 · -4020.31%
- Op Income
- $-142,899,000
- FCF YoY
- -250.70%
- 52W High
- $53.65
- 52W Low
- $11.34
- 50D MA
- $25.98
- 200D MA
- $34.25
- Beta
- 2.14
- Avg Volume
- 726.16K
Get TickerSpark's AI analysis on MAZE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Bernstein Harold | other | 14,609 |
| Jul 1, 26 | Bernstein Harold | other | 14,609 |
| Jul 1, 26 | Bernstein Harold | sell | 13,409 |
| Jul 1, 26 | Bernstein Harold | sell | 1,200 |
| Jul 1, 26 | Coloma Jason V | sell | 30,311 |
| Jul 1, 26 | Coloma Jason V | sell | 1,597 |
| Jul 1, 26 | Coloma Jason V | sell | 2,593 |
| Jun 29, 26 | Dandekar Atul | other | 7,500 |
| Jun 29, 26 | Dandekar Atul | other | 7,500 |
| Jun 29, 26 | Dandekar Atul | sell | 7,500 |
Our MAZE coverage
Recent articles, reports, and earnings notes.
No research on MAZE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAZE report →Similar companies
Peers in the same neighborhood.